Quantcast
Last updated on April 17, 2014 at 10:35 EDT

Latest Factor X Stories

2013-12-13 20:22:10

New Kcentra Label Includes Urgent Reversal of Warfarin in an Emergency Surgery Setting KING OF PRUSSIA, Pa., Dec. 13, 2013 /PRNewswire/ -- CSL Behring today announced that Kcentra(®) (Prothrombin Complex Concentrate [Human]) has received U.S. Food and Drug Administration (FDA) approval for an expanded indication -- urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients needing an urgent surgery or...

2013-12-09 20:22:42

Data Presented at the American Society of Hematology (ASH) Annual Meeting NEW ORLEANS, Dec. 9, 2013 /PRNewswire/ -- Data presented today by CSL Behring at the 55th Annual Meeting of the American Society of Hematology (ASH) showed Kcentra(®) (Prothrombin Complex Concentrate [Human]) was superior to plasma, the current standard of care in the U.S., in adult patients taking vitamin K antagonist therapy (VKA; e.g., warfarin) who required warfarin reversal prior to an urgent surgery or...

2013-09-30 23:28:04

Reportbuyer.com just published a new market research report: Point of Care Coagulation Testing: World Market 2013-2023 London (PRWEB) September 30, 2013 Report Details In 2011, the global point of care diagnostics market was worth $13.8bn, with high single-digit growth from the year before. Despite being a vast and mature market, there are number of sectors likely to experience fast growth during the next 10 years. Much of this growth is linked to the prevalence of a number of diseases...

2013-08-13 12:26:33

Designation Recognizes Kcentra as an Important New Advance for Urgent Reversal of Warfarin in Adult Patients with Acute Major Bleeding while Improving Patient Access KING OF PRUSSIA, Pa., Aug. 13, 2013 /PRNewswire/ -- CSL Behring today announced that the Centers for Medicare and Medicaid Services (CMS) has approved a new technology add-on payment (NTAP) for Kcentra(TM) (Prothrombin Complex Concentrate [Human]) for use in the inpatient hospital setting for the urgent reversal of...

2013-06-27 23:52:49

Rockville, MD | 6/26/2013 | PRWeb – MarketResearch.com announces the addition of a new market research report in Pharmaceuticals to their product offering: New Oral Anticoagulants Markets http://www.marketresearch.com/land/product.asp?productid=7458266&progid=85535 (PRWEB) June 26, 2013 New Oral Anticoagulants Markets TriMarkPublications.com cites in its newly published “New Oral Anticoagulants Markets” report that the global anticoagulants market will spike to over $24 billion...

2013-06-27 08:30:58

Studies will feature research on novel investigational recombinant factor VIIa, VIII and IX therapies for hemophilia A and B KING OF PRUSSIA, Pa., June 27, 2013 /PRNewswire/ -- CSL Behring today announced it will present study data from three ongoing clinical trial programs evaluating the Company's novel recombinant factor VIIa (rVIIa-FP), VIII (rVIII-SingleChain) and IX (rIX-FP) agents for people with hemophilia A and B with and without inhibitors. The data will be presented at the...

2013-06-24 08:27:23

DUBLIN, June 24, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/8xgb6k/new_oral) has announced the addition of the "New Oral Anticoagulants Markets" [http://www.researchandmarkets.com/research/8xgb6k/new_oral ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Anticoagulants can be categorized into five main modalities: low molecular weight heparins (LMWHs), herapins, warfarin, direct...

2013-04-30 12:27:15

Kcentra(TM) Is the First FDA-Approved 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in the U.S. KING OF PRUSSIA, Pa., April 30, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) approved Kcentra(TM) (Prothrombin Complex Concentrate [Human]), the first non-activated 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g.,...

2013-04-25 08:34:05

Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study MOUNT KISCO, New York, USA, and Tokyo, Japan, April 25, 2013 /PRNewswire/ -- Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban,...

2013-02-28 08:31:17

Label broadened to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital factor XIII deficiency KING OF PRUSSIA, Pa., Feb. 28, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Corifact(®), Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital...